Clinical trial NCT00153998: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
Official title: Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Colorectal Cancer
Liver Metastases
Keywords: Cetuximab
Oxaliplatin
Irinotecan
5-FU
Chemotherapy
Resection
Liver resection
Neoadjuvant
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2005-09-12
Enrollment: 135
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: General Objectives:

* To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
* To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy

Detailed description: Patients with liver metastasis will be screened for this study. Eligible patients will complete the pretreatment evaluation including an abdominal CT scan that will be presented to the local surgeon and the radiologist for proving of resectability of hepatic lesions. Additionally, CT scans will be reviewed by three reference surgeons. In case of non-resectability, as defined above, CT- or ultrasound- guided biopsy of one of the liver metastases will be performed, unless biopsy material is available from prior biopsy of one of the liver metastases.

Instead of an ultrasound-guided biopsy, a CT-guided biopsy may be performed.

Formalin-fixed, paraffin embedded metastatic tissue will be sent to reference laboratory (Prof. Störkel, Wuppertal) for immunohistochemical analysis of EGFR- expression.

Additionally tissue will be stored in "RNA later" for gene expression analysis if agreed by the patient.

Additionally, the primary tumor will be collected and sent to the reference laboratory for analysis of EGFR- expression (if agreement of the patient exists).

Patients will be randomized to a combination of:

Cetuximab/FOLFIRI (irinotecan/5-FU/FA) or Cetuximab/FOLFOX6 (oxaliplatin/5-FU/FA)

All patients receive a four month treatment (eight cycles) of the allocated treatment.

Resection is planned after completion of neoadjuvant treatment and should be performed between 4 and 6 weeks after the last dose of chemotherapy. Probes of the resected material (in liquid nitrogen and paraffin embedded material will be collected).

If a resection is not possible after eight administrations of chemotherapy, chemotherapy will be continued until tumor progression (maximal duration of treatment 2 years) and the patient will be evaluated for a potential resection every two months.

After resection, postoperative treatment is planned for 3 months (6 cycles). Treatment start is planned between 4 and 8 weeks after the operation.

Eligibility criteria: Inclusion Criteria:

* Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).
* Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.
* Karnofsky Performance Status ≥ 80
* Informed consent
* Adequate bone marrow function, liver and renal function (neutrophils \> 1.5 x 10\^9/l; thrombocytes \> 100 x 10\^9/l; hemoglobin \> 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal \[ULN\] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT \< 5 x UNL; serum creatinine ≤ 1.5 x UNL)
* Age ≥ 18 years

Exclusion Criteria:

* Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence
* Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)
* Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy
* Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry
* Concurrent systemic immune therapy, chemotherapy, or hormone therapy
* Investigational agents or participation in clinical trials within 30 days before start of the treatment in study
* Clinically relevant coronary disease or myocardial infarction within 12 months before study entry
* Peripheral neuropathy \> CTC grade I
* Inflammatory bowel disease
* Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
* History of severe psychiatric illness
* Drug or alcohol abuse
* Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)

Primary outcomes:
measure: Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population
Secondary outcomes:
measure: Rate of R0 liver resection (ITT- population)
measure: Progression free survival (ITT- population)
measure: Disease free survival after resection (ITT- population)
measure: Overall survival (ITT- population)
measure: Safety (all patients that received any study drug)
measure: Molecular predictive markers for response and toxicity
Other outcomes:
Locations:
city: Wien
country: Austria
facility: Medizinische Universitaet Wien, Universitaetsklinik für Chirurgie
city: Aschersleben
country: Germany
facility: Kreiskrankenhaus Aschersleben
city: Berlin
country: Germany
facility: Charite-Campus Benjamin Franklin, Innere Medizin
city: Berlin
country: Germany
facility: Charite-Campus, Virchow-Klinikum, Innere Medizin
city: Celle
country: Germany
facility: Allgemeines Krankenhaus Celle
city: Dresden
country: Germany
facility: University Hospital "Carl Gustav Carus"
city: Duesseldorf
country: Germany
facility: Florence-Nightingale-Krankenhaus
city: Erlangen
country: Germany
facility: Universitaet Erlangen-Nuernberg, Chirurgie
city: Essen
country: Germany
facility: Westdeutsches Tumorzentrum, Universitaetsklinikum Essen
city: Frankfurt Main
country: Germany
facility: Johann Wolfgang Goethe Universitaet, Chirurgie
city: Kaiserslautern
country: Germany
facility: Westpfalz-Klinikum GmbH Innere Medizin I
city: Kiel
country: Germany
facility: UKSH Campus Kiel, II. Medizinische Klinik
city: Magdeburg
country: Germany
facility: Staedtisches Klinikum Magdeburg-Olvenstedt
city: Mannheim
country: Germany
facility: Universitaetsklinik Mannheim gGmbH, III. Medizinische Klinik
city: Muenchen
country: Germany
facility: Klinikum Grosshadern, III. Medizinische Klinik
city: Oldenburg
country: Germany
facility: Klinikum Oldenburg GmbH
city: Passau
country: Germany
facility: Klinikum Passau, II. Medizinische Klinik
city: Stralsund
country: Germany
facility: Klinikum der Hansestadt Stralsund GmbH, Medizinische Klinik
city: Trier
country: Germany
facility: Krankenhaus der Barmherzigen Brueder Trier, Chirurgie
city: Tuebingen
country: Germany
facility: Universitaetsklinikum Tuebingen
city: Wuerzburg
country: Germany
facility: Universitaetsklinikum Wuerzburg, Chirurgie
Study officials:
affiliation: Klinikum Oldenburg GmbH, Dr.-Eden-Str.10; 26133 Oldenburg
name: Claus-Henning Köhne, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany
name: Gunnar Folprecht, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.
citation: Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Kohne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.